Full Text View
Tabular View
No Study Results Posted
Related Studies
Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
This study has been completed.
Study NCT00001646   Information provided by National Institutes of Health Clinical Center (CC)
First Received: November 3, 1999   Last Updated: March 3, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acquired Immunodeficiency Syndrome
Aspergillosis
HIV Infections
Immunologic Deficiency Syndromes
Neutropenia
Additional conditions recognized in this trial
Infection
Syndrome
More general conditions related to this trial
Agranulocytosis
Disease
Hematologic Diseases
Immune System Diseases
Lentivirus Infections
Leukocyte Disorders
Leukopenia
Mycoses
Pathologic Processes
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
Voriconazole
Amphotericin B
Additional drug interventions recognized in this trial
Abelcet
Liposomal amphotericin B
More general drug interventions related to this trial
Amebicides
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antifungal
Antifungal Agents
Antiparasitic Agents
Antiprotozoal Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services